
News|Videos|September 21, 2023
CHRYSALIS-2: Amivantamab + Lazertinib in Non–Small Cell Lung Cancer
Key opinion leaders review data from the CHRYSALIS-2 trial and consider the optimal utilization of amivantamab and lazertinib in combination in the setting of non–small cell lung cancer management.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































